End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.62 USD | +5.48% | +4.05% | -14.76% |
May. 15 | Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 06 | Sagimet Biosciences Names Thierry Chauche CFO | MT |
Business Summary
Number of employees: 9
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics for the Treatment of Non-alcoholic Steatohepatitis and Other Diseases
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Happel
CEO | Chief Executive Officer | 62 | 22-10-23 |
George Kemble
CHM | Chairman | 63 | 11-08-14 |
Elizabeth Rozek
CMP | Compliance Officer | 53 | 23-03-31 |
Chief Tech/Sci/R&D Officer | - | 12-12-31 | |
Chief Tech/Sci/R&D Officer | 61 | 21-01-31 | |
Merdad Parsey
BRD | Director/Board Member | 61 | 10-09-29 |
Gaeton Biscardi
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 07-03-31 |
Richard Rodgers
BRD | Director/Board Member | 57 | 15-02-28 |
Director/Board Member | 60 | 21-03-31 | |
David Happel
CEO | Chief Executive Officer | 62 | 22-10-23 |
Jinzi Wu
BRD | Director/Board Member | 61 | 19-01-31 |
George Kemble
CHM | Chairman | 63 | 11-08-14 |
Merdad Parsey
BRD | Director/Board Member | 61 | 10-09-29 |
- | - | ||
- | - | ||
- | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,520,490 | 0 | 0 | 81.59 % |
Stock B | 1 | 30,394,655 | 26,040,810 ( 85.68 %) | 0 |
Company contact information
Sagimet Biosciences, Inc.
155 Bovet Road Suite 303
94402, San Mateo
+650-561-8600
http://www.sagimet.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.76% | 147M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.90% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- SGMT Stock
- Company Sagimet Biosciences Inc.